to improve shared decision-making between patients and physicians. However, there is limited research on the relevancies of the numerous available PROs to patients with PDAC and whether these align with what their physicians believe are patient
Search Results
Michelle Guan, Gillian Gresham, Arvind Shinde, Isaac Lapite, Jun Gong, Veronica R. Placencio-Hickok, Christopher B. Forrest, and Andrew E. Hendifar
Tara M. Mackay, Lennart B. van Rijssen, Jurr O. Andriessen, Mustafa Suker, Geert-Jan Creemers, Ferry A. Eskens, Ignace H. de Hingh, Lonneke V. van de Poll-Franse, Mirjam A.G. Sprangers, Olivier R. Busch, Johanna W. Wilmink, Casper H. van Eijck, Marc G. Besselink, Hanneke W. van Laarhoven, and on behalf of the Dutch Pancreatic Cancer Group
suggested that improved information provision is important. 31 – 36 In fact, information provision is a prerequisite of shared decision-making, which, in turn, has been related to satisfaction with care. 8 , 28 , 37 Additionally, if patients are well
Stefanie L. Thorsness, Azael Freites-Martinez, Michael A. Marchetti, Cristian Navarrete-Dechent, Mario E. Lacouture, and Emily S. Tonorezos
cancer survivors who have in-field NMSC with low-risk histologic and clinical features, dermatologic therapy options with lower costs and risks should be considered in the shared decision-making process. Limitations of this study include a study
Christina D. Williams, William M. Grady, and Leah L. Zullig
screening rates are suboptimal, with at least one-third of eligible patients having never been screened, the USPSTF asserts that the “best screening test is the one that gets done.” Shared decision-making is an approach to choosing the “best” and preferred
Robert B. Hines, Alina Barrett, Philip Twumasi-Ankrah, Dominique Broccoli, Kimberly K. Engelman, Joaquina Baranda, Elizabeth A. Ablah, Lisette Jacobson, Michelle Redmond, Wei Tu, and Tracie C. Collins
highlight the need for improved physician-patient communication during the clinical encounter to inform the treatment plan. A shared decision-making process has been advocated to improve patient perceptions of the quality of the care experience and to
Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, and Melissa M. Hudson
randomized clinical trials given the short duration of follow-up relative to the long latency to incident late effects. Simulation models offer one avenue for estimating an individual’s risk for a given late effect and can be integrated into shared decision-making
Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group
Background Older adults have the highest incidence of cancer and represent the fastest growing group of individuals requiring cancer surgery. 1 – 3 Shared decision-making with older adults, in particular regarding surgery, has inherent
Maxwell T. Vergo and Al B. Benson III
absolute benefits patients may expect from adjuvant therapy in their situation. This can be weighed against known long-term adverse effects from receiving adjuvant chemotherapy, optimizing the shared decision-making process between patient and physician
Presenters: Benjamin O. Anderson and Janice A. Lyons
, and whose RT can be limited to the breast and not include the nodes, Dr. Lyons added. She emphasized that shared decision-making is critical in situations such as this. “The patient may want to accept a higher risk of locoregional recurrence versus
Andrew T. Kuykendall and Rami Komrokji
routinely recommend cytoreductive therapy; however, this is another situation in which shared decision-making is vital. Broadly speaking, the lack of consensus regarding the impact of platelet count in ET suggests this is a complex relationship that is
